{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:38:14Z","timestamp":1778863094259,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T00:00:00Z","timestamp":1411689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment of neuroblastoma with targeted immunotherapy using chimeric anti\u2010GD2 monoclonal antibodies (ch14.18) is associated with significant pain requiring management with a high\u2010dose opioid infusion. We present a case series of six children, for whom dexmedetomidine and hydromorphone infusions safely and effectively reduced the pain of ch14.18 therapy in the oncology ward setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>The ch14.18 infusion is administered for \u226510\u2009hr over four consecutive days in each of 5 cycles. Hydromorphone (2\u20138\u2009mcg.kg<jats:sup>\u22121<\/jats:sup>.hr<jats:sup>\u22121<\/jats:sup>) and dexmedetomidine (0.1\u20130.6\u2009mcg.kg<jats:sup>\u22121<\/jats:sup>.hr<jats:sup>\u22121<\/jats:sup>) infusions were commenced 1\u2009hr before starting ch14.18 immunotherapy and titrated to optimal clinical effect. One hour after stopping the ch14.18 infusion, dexmedetomidine was discontinued and hydromorphone weaned as tolerated. This strategy was supervised by the Acute Pain Service with strict monitoring and nursing policies. Patient charts were reviewed for evidence of side effects and quality of analgesia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from six patients, with median (range) age of 3.5 (2\u201312) years are reported. Median (range) utilization of hydromorphone was 2.9 (2.0\u20134.7) mcg.kg<jats:sup>\u22121<\/jats:sup>.hr<jats:sup>\u22121<\/jats:sup>, and of dexmedetomidine was 0.17 (0.10\u20130.20) mcg.kg<jats:sup>\u22121<\/jats:sup>.hr<jats:sup>\u22121<\/jats:sup>. A drop in mean arterial pressure \u226530% below baseline was identified during 30% of treatment days, but only prompted interrupting or reducing the ch14.18 infusion on 7% of treatment days; only one episode of grade 3 hypotension was recorded during this series. Hypoxemia occurred during 8% and bradycardia during 4% of treatment days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dexmedetomidine infusion may be an effective and safe pain management adjunct to opioid therapy for the pain of ch14.18 infusion. Pediatr Blood Cancer 2015;62:29\u201334. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.25197","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T20:59:32Z","timestamp":1411765172000},"page":"29-34","source":"Crossref","is-referenced-by-count":22,"title":["Dexmedetomidine and hydromorphone: A novel pain management strategy for the oncology ward setting during anti\u2010GD2 immunotherapy for high\u2010risk neuroblastoma in children"],"prefix":"10.1002","volume":"62","author":[{"given":"Matthias","family":"G\u00f6rges","sequence":"first","affiliation":[{"name":"Department of Electrical and Computer Engineering University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"West","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Deyell","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology\/BMT BC Children's Hospital Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Winton","sequence":"additional","affiliation":[{"name":"Royal Hospital for Sick Children Edinburgh United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Lauder","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Vancouver Canada"},{"name":"Department of Anesthesia BC Children's Hospital Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.11.011"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411601"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925"},{"key":"e_1_2_6_5_1","first-page":"144","article-title":"Effect of a chimeric anti\u2010ganglioside GD2 antibody on cell\u2010mediated lysis of human neuroblastoma cells","volume":"51","author":"Barker E","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8861"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2169"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.3564"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.24.4077"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.143"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199710000-00014"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2009.03207.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31822b8629"},{"key":"e_1_2_6_15_1","unstructured":"Health Canada.Summary Basis of Decision (SBD) PrPRECEDEX\u2122;2010."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.03.029"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/pan.12030"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2011.03575.x"},{"key":"e_1_2_6_19_1","first-page":"140","article-title":"Clinical validation of FLACC: Preverbal patient pain scale","volume":"29","author":"Manworren RCB","journal-title":"Pediatr Nurs"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00314-1"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.12.008"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31825681cb"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1213\/ANE.0b013e3181ee82fa","article-title":"Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy","volume":"111","author":"Patel A","year":"2010","journal-title":"Anesth Analg"},{"key":"e_1_2_6_24_1","unstructured":"KeenK CampbellF WalkerS.Analgesic requirements during anti\u2010GD2 antibody immunotherapy for neuroblastoma. International symposium on pediatric pain. Stockholm;2013."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.4423"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25197","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.25197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T18:18:26Z","timestamp":1696529906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,26]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1002\/pbc.25197"],"URL":"https:\/\/doi.org\/10.1002\/pbc.25197","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,26]]}}}